Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request, 11449-11451 [2023-03513]
Download as PDF
Federal Register / Vol. 88, No. 36 / Thursday, February 23, 2023 / Notices
duration of comments may be limited by
time constraints.
Streaming Webcast of the Public
Meeting: This public meeting will be
streamed via a webcast in both English
and Spanish languages. Please register
for the webcast by visiting https://
www.surveymonkey.com/r/
LongCOVIDPFDD.
The English-language webcast can be
accessed via: https://fda.yorkcast.com/
webcast/Play/4eba453a2412474
e98fff1fabcc63ac51d. The Spanishlanguage webcast can be accessed via:
https://fda.yorkcast.com/webcast/Play/
0385884d5655420fabd3a55a
237926691d. Simply click on the link
and hit the ‘‘play’’ button and it will
start. A test signal will be playing 30
minutes prior to the event, so you can
click on the link at any point during that
time to start. You will hear music
playing during the test period and then
the event will begin at 10 a.m. ET. If you
would like to check your system now,
you can click on the link and the page
will open with a ‘‘waiting’’ statement
showing.
Transcripts: Please be advised that as
soon as a transcript of the public
meeting is available, it will be accessible
on the meeting website at https://
www.fda.gov/drugs/news-eventshuman-drugs/public-meeting-patientfocused-drug-development-long-covid04252023.
Dated: February 16, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–03714 Filed 2–22–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–D–0451]
Labeling of Plant-Based Milk
Alternatives and Voluntary Nutrient
Statements; Draft Guidance for
Industry; Availability; Agency
Information Collection Activities;
Proposed Collection; Comment
Request
AGENCY:
Food and Drug Administration,
HHS.
lotter on DSK11XQN23PROD with NOTICES1
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or we) is
announcing the availability of a draft
guidance for industry entitled ‘‘Labeling
of Plant-based Milk Alternatives and
Voluntary Nutrient Statements:
Guidance for Industry.’’ The draft
SUMMARY:
VerDate Sep<11>2014
17:12 Feb 22, 2023
Jkt 259001
guidance, when finalized, will provide
industry with our view on the naming
of plant-based food products that are
marketed and sold as alternatives to
milk (plant-based milk alternatives) and
our recommendations on the use of
voluntary nutrient statements.
Industry’s use of these
recommendations for labeling plantbased milk alternatives will provide
consumers with additional nutrition
information to help them understand
certain nutritional differences between
these products and milk and make
informed dietary choices. This draft
guidance is not final nor is it in effect
at this time.
DATES: Submit either electronic or
written comments on the draft guidance
by April 24, 2023 to ensure that FDA
considers your comment on the draft
guidance before it begins work on the
final version of the guidance. Submit
electronic or written comments on the
proposed collection of information in
the draft guidance by April 24, 2023.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
11449
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2023–D–0451 for ‘‘Labeling of Plantbased Milk Alternatives and Voluntary
Nutrient Statements: Guidance for
Industry; Agency Information Collection
Activities; Proposed Collection;
Comment Request.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ We
will review this copy, including the
claimed confidential information, in our
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
E:\FR\FM\23FEN1.SGM
23FEN1
11450
Federal Register / Vol. 88, No. 36 / Thursday, February 23, 2023 / Notices
lotter on DSK11XQN23PROD with NOTICES1
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the Office
of Nutrition and Food Labeling (HFS–
800), Center for Food Safety and
Applied Nutrition, Food and Drug
Administration, 5001 Campus Dr.,
College Park, MD 20740. Send two selfaddressed adhesive labels to assist that
office in processing your request. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance.
FOR FURTHER INFORMATION CONTACT:
With regard to the draft guidance:
Jeanmaire Hryshko, Center for Food
Safety and Applied Nutrition, Office of
Nutrition and Food Labeling (HFS–800),
Food and Drug Administration, 5001
Campus Dr., College Park, MD 20740,
240–402–2371; or Meadow Platt, Center
for Food Safety and Applied Nutrition,
Office of Regulations and Policy (HFS–
024), Food and Drug Administration,
5001 Campus Dr., College Park, MD
20740, 240–402–2378.
With regard to the proposed collection
of information: Domini Bean, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
5733, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
An increase in purchase and
consumption of plant-based milk
alternatives has occurred over the last
10 years. Many products are labeled
with names that include the term
‘‘milk.’’ Plant-based milk alternatives
are made from liquid-based extracts of
plant materials, such as tree nuts,
legumes, seeds, or grains. FDA has
established a standard of identity or
compositional requirements for milk
(see 21 CFR 131.110) but has not
established standards of identity or
compositional requirements for plantbased milk alternatives. The
composition, including the nutrient
profile, of these plant-based milk
alternative products varies depending
on the plant source(s), processing
methods, and added ingredients.
We are committed to clear and
transparent food labels that are truthful
and not misleading. We are also
committed to using our tools and
authorities to empower consumers with
VerDate Sep<11>2014
17:12 Feb 22, 2023
Jkt 259001
information to quickly ascertain the
types of products they are purchasing
for themselves and their families and
enhance their ability to make informed
choices about the foods they buy and
eat. To further this goal, in the Federal
Register of September 28, 2018 (83 FR
49103), FDA issued a notice requesting
comment on the labeling of plant-based
alternatives with names that include the
names of dairy foods. We invited
comment on a variety of issues,
including how consumers use plantbased dairy alternatives, how consumers
understand terms included in the names
of plant-based dairy alternatives, and
whether consumers are aware of and
understand differences between plantbased dairy alternatives and their dairy
counterparts. We received over 13,000
comments, which helped to inform the
development of this draft guidance.
We are announcing the availability of
a draft guidance for industry entitled
‘‘Labeling of Plant-based Milk
Alternatives and Voluntary Nutrient
Statements: Guidance for Industry.’’ The
draft guidance provides our view on the
naming of plant-based milk alternatives
and recommendations on voluntary
nutrient statements for the labeling of
these products. The draft guidance does
not address other plant-based dairy
alternatives such as plant-based cheese,
yogurt, or kefir alternatives. The draft
guidance is limited to plant-based milk
alternatives because: (1) most comments
and consumer research submitted to the
notice were limited to plant-based milk
alternatives; (2) the overall market for
plant-based milk alternatives is greater
than the market for other plant-based
dairy alternatives such as yogurts and
cheeses; and (3) data indicates that
consumers may not understand the
nutritional differences between plantbased milk alternatives and a potential
public health concern may exist if plantbased milk alternatives are substituted
for milk.
We are issuing the draft guidance
consistent with our good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent our current thinking on this
topic. It does not establish any rights for
any person and is not binding on FDA
or the public. You can use an alternate
approach if it satisfies the requirements
of the applicable statutes and
regulations.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
II. Paperwork Reduction Act of 1995
Under the Paperwork Reduction Act
of 1995 (PRA) (44 U.S.C. 3501–3521),
Federal Agencies must obtain approval
from the Office of Management and
Budget (OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Labeling of Plant-Based Milk
Alternatives and Voluntary Nutrient
Statements: Guidance for Industry
OMB Control Number 0910–0381
This draft guidance, once finalized,
provides recommendations on the
naming of plant-based milk alternatives
and on voluntary nutrient statements for
the labeling of these products. The draft
guidance’s recommendations for
labeling plant-based beverages that are
used in place of milk will provide
consumers with additional nutrition
information to help them compare these
products to milk and make informed
dietary choices.
We estimate the burden of this
collection of information as follows:
E:\FR\FM\23FEN1.SGM
23FEN1
11451
Federal Register / Vol. 88, No. 36 / Thursday, February 23, 2023 / Notices
TABLE 1—ESTIMATED THIRD-PARTY DISCLOSURE BURDEN
Number of
respondents
Activity
Labeling recommendations in ‘‘Best Practices for
Labeling of Plant-based Milk Alternatives’’ ......
I
56
Number of
disclosures per
respondent
Total annual
disclosures
6
336
I
Average
burden per
disclosure
I
1
Total
capital
costs 1 2
Total hours
I
336
I
$500,000
1 One-time
relabeling costs.
2 There are no operating and maintenance costs associated with this collection of information.
The estimates in table 1 are based on
our experience with similar labeling
programs. We estimate that each year 56
manufacturers will relabel their
products following recommendations
found in the draft guidance. We
estimate that each manufacturer will
relabel 6 products for 336 total annual
disclosures (56 manufacturers × 6
labels). Each disclosure will take an
estimated 1 hour to complete for an
annual third-party disclosure burden of
336 hours (336 disclosures × 1 hour).
We estimate that there will be an annual
capital cost of $500,000 associated with
relabeling. This is the cost of designing
a revised label and incorporating it into
the manufacturing process. We believe
that this will be a one-time burden per
respondent.
lotter on DSK11XQN23PROD with NOTICES1
III. Other Issues for Consideration
Although FDA welcomes comments
on any aspect of the guidance, we
particularly invite comment on the
following:
• The voluntary nutrient statement
recommendations provided in section
III.2 of the draft guidance. We
acknowledge that the labeling of some
plant-based milk alternatives may have
space constraints that limit listing of
multiple nutrients in the voluntary
nutrient statement. Therefore, we are
interested in comments about the
placement of and possible space
constraints for the voluntary nutrient
statement on product labels.
• FDA is recommending nutrient
disclosure statements on the labels of
plant-based milk alternatives that
contain less of the following nutrients
compared to milk: calcium, protein,
vitamin A, vitamin D, magnesium,
phosphorus, potassium, riboflavin, and
vitamin B12. We chose these specific
nutrients because the Dietary Guidelines
for Americans identifies the Dairy
Group as being a key contributor of
those nutrients and to align with the
nutritional standards set by the U.S.
Department of Agriculture’s (USDA)
Food and Nutrition Service for fluid
milk substitutes served in the National
School Lunch Program, School
Breakfast Program, and Child and Adult
Care Food Program (USDA criteria) (see
VerDate Sep<11>2014
17:12 Feb 22, 2023
Jkt 259001
7 CFR 210.10(d)(3), 220.8(d), and
226.20(g)(3)).
• For the purpose of this draft
guidance, are the USDA criteria that
identifies minimum levels of nutrients
for fluid milk substitutes the most
appropriate criteria to use? If yes, why?
If not, what criteria (i.e., nutrients and
nutrient levels, minimums versus ranges
of nutrient levels, etc.) should we
consider and why? Please provide
information, research, and data to help
us understand your reasoning.
IV. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/food/guidance-regulationfood-and-dietary-supplements/
guidance-documents-regulatoryinformation-topic-food-and-dietarysupplements, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: February 15, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–03513 Filed 2–22–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Global Affairs: Stakeholder
Listening Session for the
Intergovernmental Negotiating Body
(INB) To Draft and Negotiate a WHO
Convention, Agreement or Other
International Instrument on Pandemic
Prevention, Preparedness and
Response
Notice of public listening
session; request for comments.
ACTION:
The listening session will be
held on Wednesday, March 15, 2023,
from 12:00 p.m. to 2:00 p.m., Eastern
Daylight Time.
ADDRESSES: The session will be held
virtually, with online slide share and
dial-in information shared with
registered participants.
Status: This meeting is open to the
public, but requires RSVP to
DATES:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
OGA.RSVP@hhs.gov by March 6, 2023.
See RSVP section below for details.
SUPPLEMENTARY INFORMATION:
Purpose: The U.S. Department of
Health and Human Services (HHS) and
the Department of State are charged
with co-leading the U.S. delegation to
the Intergovernmental Negotiating Body
to draft and negotiate a WHO
convention, agreement or other
international instrument on pandemic
prevention, preparedness and response
and will convene an informal
Stakeholder Listening Session.
The Stakeholder Listening Session is
designed to seek input from
stakeholders and subject matter experts
to help inform and prepare for U.S.
government engagement with the
Intergovernmental Negotiating Body.
Matters To Be Discussed: The
listening session will discuss potential
areas that could be included in a
pandemic accord to promote pandemic
prevention, preparedness, and response.
Topics will include those found in the
Zero Draft of the Pandemic Accord. The
Zero draft of the Intergovernmental
Negotiating Body (INB) can be found at
this website: https://apps.who.int/gb/
inb/. Participation is
welcome from stakeholder
communities, including:
• Public health and advocacy groups
• State, local, and Tribal groups
• Private industry
• Minority health organizations
• Academic and scientific
organizations, etc.
RSVP: Persons seeking to attend or
speak at the listening session must
register by March 6, 2023.
Registrants must include their full
name and organization, if any, and
indicate whether they are registering as
a listen-only attendee or as a speaker
participant to OGA.RSVP@hhs.gov.
Requests to participate as a speaker
must include:
1. The name of the person desiring to
participate;
2. The organization(s) that person
represents, if any;
3. Identification of the primary topic
of interest.
E:\FR\FM\23FEN1.SGM
23FEN1
Agencies
[Federal Register Volume 88, Number 36 (Thursday, February 23, 2023)]
[Notices]
[Pages 11449-11451]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-03513]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-D-0451]
Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient
Statements; Draft Guidance for Industry; Availability; Agency
Information Collection Activities; Proposed Collection; Comment Request
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing the
availability of a draft guidance for industry entitled ``Labeling of
Plant-based Milk Alternatives and Voluntary Nutrient Statements:
Guidance for Industry.'' The draft guidance, when finalized, will
provide industry with our view on the naming of plant-based food
products that are marketed and sold as alternatives to milk (plant-
based milk alternatives) and our recommendations on the use of
voluntary nutrient statements. Industry's use of these recommendations
for labeling plant-based milk alternatives will provide consumers with
additional nutrition information to help them understand certain
nutritional differences between these products and milk and make
informed dietary choices. This draft guidance is not final nor is it in
effect at this time.
DATES: Submit either electronic or written comments on the draft
guidance by April 24, 2023 to ensure that FDA considers your comment on
the draft guidance before it begins work on the final version of the
guidance. Submit electronic or written comments on the proposed
collection of information in the draft guidance by April 24, 2023.
ADDRESSES: You may submit comments on any guidance at any time as
follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2023-D-0451 for ``Labeling of Plant-based Milk Alternatives and
Voluntary Nutrient Statements: Guidance for Industry; Agency
Information Collection Activities; Proposed Collection; Comment
Request.'' Received comments will be placed in the docket and, except
for those submitted as ``Confidential Submissions,'' publicly viewable
at https://www.regulations.gov or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We will review
this copy, including the claimed confidential information, in our
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information to be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify this information as ``confidential.''
Any information marked as ``confidential'' will not be disclosed except
in accordance with 21 CFR 10.20 and other applicable disclosure law.
For more information about FDA's posting of comments to public dockets,
see 80 FR 56469, September 18, 2015, or access the information at:
https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
[[Page 11450]]
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of the draft guidance to
the Office of Nutrition and Food Labeling (HFS-800), Center for Food
Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus
Dr., College Park, MD 20740. Send two self-addressed adhesive labels to
assist that office in processing your request. See the SUPPLEMENTARY
INFORMATION section for electronic access to the draft guidance.
FOR FURTHER INFORMATION CONTACT:
With regard to the draft guidance: Jeanmaire Hryshko, Center for
Food Safety and Applied Nutrition, Office of Nutrition and Food
Labeling (HFS-800), Food and Drug Administration, 5001 Campus Dr.,
College Park, MD 20740, 240-402-2371; or Meadow Platt, Center for Food
Safety and Applied Nutrition, Office of Regulations and Policy (HFS-
024), Food and Drug Administration, 5001 Campus Dr., College Park, MD
20740, 240-402-2378.
With regard to the proposed collection of information: Domini Bean,
Office of Operations, Food and Drug Administration, Three White Flint
North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-
5733, [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
An increase in purchase and consumption of plant-based milk
alternatives has occurred over the last 10 years. Many products are
labeled with names that include the term ``milk.'' Plant-based milk
alternatives are made from liquid-based extracts of plant materials,
such as tree nuts, legumes, seeds, or grains. FDA has established a
standard of identity or compositional requirements for milk (see 21 CFR
131.110) but has not established standards of identity or compositional
requirements for plant-based milk alternatives. The composition,
including the nutrient profile, of these plant-based milk alternative
products varies depending on the plant source(s), processing methods,
and added ingredients.
We are committed to clear and transparent food labels that are
truthful and not misleading. We are also committed to using our tools
and authorities to empower consumers with information to quickly
ascertain the types of products they are purchasing for themselves and
their families and enhance their ability to make informed choices about
the foods they buy and eat. To further this goal, in the Federal
Register of September 28, 2018 (83 FR 49103), FDA issued a notice
requesting comment on the labeling of plant-based alternatives with
names that include the names of dairy foods. We invited comment on a
variety of issues, including how consumers use plant-based dairy
alternatives, how consumers understand terms included in the names of
plant-based dairy alternatives, and whether consumers are aware of and
understand differences between plant-based dairy alternatives and their
dairy counterparts. We received over 13,000 comments, which helped to
inform the development of this draft guidance.
We are announcing the availability of a draft guidance for industry
entitled ``Labeling of Plant-based Milk Alternatives and Voluntary
Nutrient Statements: Guidance for Industry.'' The draft guidance
provides our view on the naming of plant-based milk alternatives and
recommendations on voluntary nutrient statements for the labeling of
these products. The draft guidance does not address other plant-based
dairy alternatives such as plant-based cheese, yogurt, or kefir
alternatives. The draft guidance is limited to plant-based milk
alternatives because: (1) most comments and consumer research submitted
to the notice were limited to plant-based milk alternatives; (2) the
overall market for plant-based milk alternatives is greater than the
market for other plant-based dairy alternatives such as yogurts and
cheeses; and (3) data indicates that consumers may not understand the
nutritional differences between plant-based milk alternatives and a
potential public health concern may exist if plant-based milk
alternatives are substituted for milk.
We are issuing the draft guidance consistent with our good guidance
practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent our current thinking on this topic. It does
not establish any rights for any person and is not binding on FDA or
the public. You can use an alternate approach if it satisfies the
requirements of the applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-
3521), Federal Agencies must obtain approval from the Office of
Management and Budget (OMB) for each collection of information they
conduct or sponsor. ``Collection of information'' is defined in 44
U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or
requirements that members of the public submit reports, keep records,
or provide information to a third party. Section 3506(c)(2)(A) of the
PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a
60-day notice in the Federal Register concerning each proposed
collection of information before submitting the collection to OMB for
approval. To comply with this requirement, FDA is publishing notice of
the proposed collection of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient
Statements: Guidance for Industry
OMB Control Number 0910-0381
This draft guidance, once finalized, provides recommendations on
the naming of plant-based milk alternatives and on voluntary nutrient
statements for the labeling of these products. The draft guidance's
recommendations for labeling plant-based beverages that are used in
place of milk will provide consumers with additional nutrition
information to help them compare these products to milk and make
informed dietary choices.
We estimate the burden of this collection of information as
follows:
[[Page 11451]]
Table 1--Estimated Third-Party Disclosure Burden
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total
Number of Number of Total annual Average capital
Activity respondents disclosures per disclosures burden per Total hours costs \1\
respondent disclosure \2\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Labeling recommendations in ``Best Practices for Labeling of 56 6 336 1 336 $500,000
Plant-based Milk Alternatives''............................
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ One-time relabeling costs.
\2\ There are no operating and maintenance costs associated with this collection of information.
The estimates in table 1 are based on our experience with similar
labeling programs. We estimate that each year 56 manufacturers will
relabel their products following recommendations found in the draft
guidance. We estimate that each manufacturer will relabel 6 products
for 336 total annual disclosures (56 manufacturers x 6 labels). Each
disclosure will take an estimated 1 hour to complete for an annual
third-party disclosure burden of 336 hours (336 disclosures x 1 hour).
We estimate that there will be an annual capital cost of $500,000
associated with relabeling. This is the cost of designing a revised
label and incorporating it into the manufacturing process. We believe
that this will be a one-time burden per respondent.
III. Other Issues for Consideration
Although FDA welcomes comments on any aspect of the guidance, we
particularly invite comment on the following:
The voluntary nutrient statement recommendations provided
in section III.2 of the draft guidance. We acknowledge that the
labeling of some plant-based milk alternatives may have space
constraints that limit listing of multiple nutrients in the voluntary
nutrient statement. Therefore, we are interested in comments about the
placement of and possible space constraints for the voluntary nutrient
statement on product labels.
FDA is recommending nutrient disclosure statements on the
labels of plant-based milk alternatives that contain less of the
following nutrients compared to milk: calcium, protein, vitamin A,
vitamin D, magnesium, phosphorus, potassium, riboflavin, and vitamin
B12. We chose these specific nutrients because the Dietary Guidelines
for Americans identifies the Dairy Group as being a key contributor of
those nutrients and to align with the nutritional standards set by the
U.S. Department of Agriculture's (USDA) Food and Nutrition Service for
fluid milk substitutes served in the National School Lunch Program,
School Breakfast Program, and Child and Adult Care Food Program (USDA
criteria) (see 7 CFR 210.10(d)(3), 220.8(d), and 226.20(g)(3)).
For the purpose of this draft guidance, are the USDA
criteria that identifies minimum levels of nutrients for fluid milk
substitutes the most appropriate criteria to use? If yes, why? If not,
what criteria (i.e., nutrients and nutrient levels, minimums versus
ranges of nutrient levels, etc.) should we consider and why? Please
provide information, research, and data to help us understand your
reasoning.
IV. Electronic Access
Persons with access to the internet may obtain the draft guidance
at https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements/guidance-documents-regulatory-information-topic-food-and-dietary-supplements, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.
Dated: February 15, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-03513 Filed 2-22-23; 8:45 am]
BILLING CODE 4164-01-P